Accéder au contenu
Merck

Genome-wide profiling of AP-1-regulated transcription provides insights into the invasiveness of triple-negative breast cancer.

Cancer research (2014-05-17)
Chunyan Zhao, Yichun Qiao, Philip Jonsson, Jian Wang, Li Xu, Pegah Rouhi, Indranil Sinha, Yihai Cao, Cecilia Williams, Karin Dahlman-Wright
RÉSUMÉ

Triple-negative breast cancer (TNBC) is an aggressive clinical subtype accounting for up to 20% of all breast cancers, but its malignant determinants remain largely undefined. Here, we show that in TNBC the overexpression of Fra-1, a component of the transcription factor AP-1, offers prognostic potential. Fra-1 depletion or its heterodimeric partner c-Jun inhibits the proliferative and invasive phenotypes of TNBC cells in vitro. Similarly, RNAi-mediated attenuation of Fra-1 or c-Jun reduced cellular invasion in vivo in a zebrafish tumor xenograft model. Exploring the AP-1 cistrome and the AP-1-regulated transcriptome, we obtained insights into the transcriptional regulatory networks of AP-1 in TNBC cells. Among the direct targets identified for Fra-1/c-Jun involved in proliferation, adhesion, and cell-cell contact, we found that AP-1 repressed the expression of E-cadherin by transcriptional upregulation of ZEB2 to stimulate cell invasion. Overall, this work illuminates the pathways through which TNBC cells acquire invasive and proliferative properties.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
MISSION® esiRNA, targeting mouse Cdh1
Sigma-Aldrich
MISSION® esiRNA, targeting human FZR1
Sigma-Aldrich
MISSION® esiRNA, targeting human CDH1
Sigma-Aldrich
MISSION® esiRNA, targeting human ZEB2